Avanos Medical (AVNS) Expected to Announce Earnings on Monday

Avanos Medical (NYSE:AVNS) is expected to issue its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $173.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 12:30 PM ET.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.06. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.The company had revenue of $182.20 million for the quarter, compared to the consensus estimate of $170.00 million. During the same period in the previous year, the business earned $0.26 earnings per share. Avanos Medical’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, analysts expect Avanos Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avanos Medical Stock Performance

NYSE:AVNS opened at $24.99 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.40 and a current ratio of 2.48. The stock has a 50-day simple moving average of $24.94 and a two-hundred day simple moving average of $19.77. The firm has a market capitalization of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $25.49.

Hedge Funds Weigh In On Avanos Medical

Several large investors have recently made changes to their positions in AVNS. Russell Investments Group Ltd. boosted its stake in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after acquiring an additional 2,307 shares during the period. Wexford Capital LP bought a new stake in Avanos Medical during the 3rd quarter valued at approximately $70,000. Tower Research Capital LLC TRC lifted its holdings in Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after purchasing an additional 5,083 shares in the last quarter. Quantessence Capital LLC purchased a new position in Avanos Medical in the 3rd quarter worth approximately $116,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Avanos Medical in the 4th quarter worth approximately $122,000. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. Wall Street Zen cut shares of Avanos Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, July 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.